Bayer AG (XETRA: BAYN) has reported new exploratory findings showing that women receiving LYNKUET (elinzanetant) for moderate to severe menopausal vasomotor symptoms experienced greater improvements in several self-reported dimensions of sleep disturbance than those receiving placebo. Presented at The Menopause Society Annual Meeting 2026 on October 26, the pooled post-hoc analysis found that the proportion of women describing their sleep quality as poor or very poor declined from 66.6% at baseline to 20.5% after 12 weeks of treatment, compared with a reduction from 57.8% to 38.7% in the placebo group.
The findings provide additional detail about sleep-related outcomes previously investigated in Bayer’s Phase 3 OASIS-1 and OASIS-2 trials, which supported the United States Food and Drug Administration approval of LYNKUET in October 2025 for moderate to severe hot flashes due to menopause. The latest analysis examined individual questions within a validated sleep-disturbance questionnaire rather than introducing a new clinical trial or demonstrating efficacy against a separately diagnosed sleep disorder.
The results are relevant because hot flashes and night sweats can interfere with sleep during menopause, creating a substantial burden beyond the immediate experience of vasomotor symptoms. However, the new item-level findings were analysed descriptively without formal statistical hypothesis testing, meaning that the observed differences should not be described as independently statistically significant.
For Bayer, the analysis strengthens the clinical understanding of an already commercialised nonhormonal menopause treatment. Its potential implications for physician awareness and patient discussions must be distinguished from regulatory evidence supporting a separate indication for insomnia or other sleep disorders, which LYNKUET does not currently possess.
What does Bayer’s post-hoc analysis reveal about sleep quality after 12 weeks of LYNKUET?
The new analysis used pooled patient-reported data from OASIS-1 and OASIS-2, two randomised, double-blind, placebo-controlled Phase 3 trials evaluating elinzanetant in women experiencing moderate to severe menopausal vasomotor symptoms.
Rather than examining a single overall sleep score, researchers investigated responses to eight individual questions within the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b questionnaire, commonly known as PROMIS SD SF 8b.
The instrument evaluates sleep-related experiences over the preceding seven days using a five-point response scale. Its questions address restless sleep, satisfaction with sleep, refreshing sleep, difficulty falling asleep, staying asleep, getting to sleep, perceived sleep amount and overall sleep quality.
Bayer reported that a greater proportion of women receiving elinzanetant experienced reductions in raw scores across all eight items by Week 12 compared with placebo.
The most detailed numerical example concerned self-reported sleep quality. Among women receiving LYNKUET, the proportion reporting poor or very poor sleep declined from 66.6% at baseline to 20.5% after 12 weeks.
In the placebo group, the corresponding proportion declined from 57.8% to 38.7%.
These figures represent absolute within-group reductions of 46.1 percentage points for elinzanetant and 19.1 percentage points for placebo. The difference in these reductions is descriptive and should not be interpreted as an adjusted treatment effect established through formal statistical testing.
The baseline proportions were also different between groups, reinforcing the importance of not treating the Week 12 figures alone as a complete comparative efficacy analysis.
The company did not provide detailed numerical results for every questionnaire item in the October announcement. Consequently, the magnitude of improvement in individual domains such as sleep initiation, refreshing sleep and sleep maintenance cannot be quantified from the disclosed summary.
The direction of the findings is consistent with the original trials’ established sleep-disturbance results. However, this additional analysis does not independently demonstrate that elinzanetant improves all aspects of sleep to the same degree or that the changes are clinically meaningful for every patient.
How does the new analysis differ from the original OASIS-1 and OASIS-2 Phase 3 sleep findings?
OASIS-1 and OASIS-2 were pivotal clinical trials involving a combined 796 women aged 40 to 65 years who experienced moderate to severe menopausal vasomotor symptoms.
Participants were randomised to receive elinzanetant 120 milligrams orally once daily or matching placebo during the initial 12-week controlled period. The trials subsequently included additional treatment follow-up, providing information beyond the period used for the primary placebo comparisons.
The co-primary efficacy endpoints evaluated changes in the frequency and severity of moderate to severe hot flashes from baseline to Weeks 4 and 12.
Sleep disturbance was assessed as a key secondary endpoint using the total T-score derived from the PROMIS SD SF 8b questionnaire. This measurement summarises multiple dimensions of self-reported sleep disturbance using a standardised scoring approach.
The original trials demonstrated statistically significant improvements in the overall sleep-disturbance score with elinzanetant compared with placebo at Week 12.
In the peer-reviewed OASIS-1 results published in JAMA, the adjusted between-treatment difference in the sleep-disturbance T-score was minus 5.6 points, with a 95% confidence interval from minus 7.2 to minus 4.0.
In OASIS-2, the corresponding difference was minus 4.3 points, with a 95% confidence interval from minus 5.8 to minus 2.9.
Both comparisons were statistically significant, with p-values below 0.001.
Those findings established a treatment-associated improvement in the overall patient-reported sleep-disturbance endpoint within the controlled trials.
The October 2026 analysis answers a narrower question: which individual aspects of the questionnaire contributed to the observed pattern of improvement?
The distinction is important because the overall endpoint had been incorporated into the original clinical study analysis, while the newly presented item-level findings were examined retrospectively.
The post-hoc analysis cannot inherit the statistical significance of the total T-score comparison. Each individual questionnaire item would require appropriate statistical evaluation before a confirmatory claim could be made about its treatment-specific effect.
The original randomised design provides a credible clinical foundation, but the new sub-analysis should be interpreted as exploratory detail within that established evidence package.
Why do menopausal hot flashes contribute to sleep disturbance, and how could LYNKUET influence the problem?
Vasomotor symptoms are associated with changes in the body’s thermoregulatory system during menopause.
Hot flashes involve sudden sensations of heat that may be accompanied by sweating, flushing and discomfort. When symptoms occur during the night, they can interrupt sleep or make it difficult to return to sleep after awakening.
Frequent nighttime symptoms may contribute to fragmented sleep, reduced perceived sleep quality and tiredness during the following day.
However, sleep disturbance during menopause can have multiple causes, including mood symptoms, chronic medical conditions, primary sleep disorders and other physiological changes. Not every sleep complaint experienced during menopause is directly caused by vasomotor symptoms.
LYNKUET is a nonhormonal medicine that antagonises neurokinin 1 and neurokinin 3 receptors. Its dual mechanism distinguishes it from treatments that inhibit only one of these pathways.
Neurokinin signalling is involved in biological processes associated with temperature regulation and other central nervous system functions. By blocking selected neurokinin receptors, elinzanetant is intended to influence pathways contributing to menopausal vasomotor symptoms.
The medicine’s demonstrated reductions in hot flash frequency and severity provide a plausible explanation for some of the improvements in sleep disturbance observed during the OASIS trials.
If nighttime hot flashes become less frequent or less severe, women may experience fewer symptom-associated interruptions, potentially improving their perception of sleep quality.
Nevertheless, the current analysis does not determine how much of the observed sleep improvement resulted directly from reduced vasomotor symptoms and how much may have involved other pharmacological effects.
It also does not establish that the medicine directly treats insomnia through an independent sleep-regulating mechanism.
The contribution of NK1 antagonism to sleep-related outcomes remains a scientific consideration that cannot be resolved by the descriptive questionnaire findings alone.
The appropriate clinical interpretation is that elinzanetant improved self-reported sleep disturbance in women being treated for menopausal vasomotor symptoms, rather than that it has demonstrated efficacy as a general sleep medicine.
Why does reliance on patient-reported sleep measures limit the conclusions that can be drawn?
Patient-reported outcome measures are important in menopause research because many symptoms are experienced subjectively and may not be fully captured through laboratory or physiological testing.
Sleep satisfaction, perceived restfulness and the burden of nighttime awakenings can have substantial effects on quality of life even when conventional clinical measurements do not identify a distinct abnormality.
PROMIS SD SF 8b is designed to capture these patient experiences through a structured questionnaire, allowing researchers to evaluate changes over time.
However, self-reported sleep disturbance is not the same as objectively measured sleep duration, sleep architecture or sleep efficiency.
Objective assessments may involve polysomnography, actigraphy or other validated methods capable of measuring physiological or behavioural features of sleep.
The October 2026 analysis did not establish that LYNKUET increased total sleep time, reduced objectively measured awakenings or altered sleep-stage distribution.
These outcomes should not be inferred from questionnaire responses about perceived sleep quality or satisfaction.
Patient-reported data can also be influenced by expectations, symptom awareness and interpretation of the questions.
Randomisation and blinding reduce some sources of bias in the underlying trials, but they do not eliminate the limitations of exploratory analyses performed after the original study design was established.
The lack of formal item-level statistical testing further restricts the conclusions that can be made about differences between treatment groups.
The findings remain useful for understanding the patient experience, but they should be viewed as descriptive evidence rather than a new demonstration of clinical efficacy.
What did the pivotal OASIS trials establish about LYNKUET’s ability to reduce menopausal hot flashes?
The principal clinical evidence supporting LYNKUET’s approval comes from its effects on moderate to severe vasomotor symptoms.
In OASIS-1, elinzanetant produced an adjusted reduction in daily hot flash frequency relative to placebo of 3.3 episodes at Week 4 and 3.2 episodes at Week 12.
In OASIS-2, the corresponding adjusted reductions were 3.0 episodes at Week 4 and 3.2 episodes at Week 12.
These treatment effects were statistically significant and supported the conclusion that the medicine reduces the frequency of moderate to severe menopausal vasomotor symptoms.
The trials also demonstrated statistically significant reductions in symptom severity.
At Week 12, approximately 71.4% of women receiving elinzanetant in OASIS-1 achieved at least a 50% reduction in moderate to severe hot flash frequency, compared with 42.0% receiving placebo.
In OASIS-2, the corresponding response rates were 74.7% and 48.3%.
These results provide the clinical efficacy foundation for the medicine’s authorised use.
The new sleep analysis therefore complements rather than replaces the primary treatment evidence.
This distinction matters commercially because the approved indication is specifically tied to moderate to severe vasomotor symptoms caused by menopause. Sleep improvement may be relevant to discussions of treatment burden, but it does not expand the authorised indication.
The United States Food and Drug Administration approved LYNKUET on October 24, 2025, based on the clinical evidence from OASIS-1, OASIS-2 and the long-term safety study OASIS-3.
The approval established elinzanetant as a prescription nonhormonal option for eligible patients experiencing moderate to severe menopausal hot flashes.
Does LYNKUET have a separate FDA indication for insomnia or sleep disturbance?
LYNKUET does not have a separate United States Food and Drug Administration indication for insomnia or for the general treatment of sleep disorders.
Its approved indication is the treatment of moderate to severe vasomotor symptoms due to menopause.
This is particularly important when interpreting the October 2026 findings because positive secondary outcomes do not automatically authorise broader therapeutic claims.
The recommended United States dosage is 120 milligrams orally once daily at bedtime, administered as two 60-milligram capsules.
The timing of administration does not make the medicine a sleep treatment. It reflects the authorised dosing instructions for a medicine with central nervous system activity and an established safety profile.
Patients receiving the medicine may report sleep-related benefits alongside reductions in hot flashes, but those observations should remain connected to the population and outcomes evaluated in the clinical trials.
Establishing a separate insomnia indication would require appropriate clinical development and regulatory evidence specifically supporting that use.
The available OASIS results do not demonstrate treatment effectiveness in patients with primary insomnia unrelated to menopausal vasomotor symptoms.
Likewise, the findings cannot automatically be extended to women with untreated sleep apnoea or other sleep disorders requiring different clinical evaluation.
For clinicians, the significance of the results lies in understanding how treatment of vasomotor symptoms may affect broader patient experiences without changing the medicine’s authorised therapeutic purpose.
How should LYNKUET’s daytime impairment and liver-related safety risks be considered alongside sleep improvements?
The possibility of improving perceived sleep quality must be considered alongside the medicine’s established central nervous system effects.
The United States prescribing information warns that LYNKUET can cause somnolence, fatigue, dizziness, vertigo, presyncope and other nervous system-related adverse reactions.
Across the three OASIS trials, nervous system effects occurred in 11.9% of patients receiving elinzanetant, compared with 3.5% receiving placebo.
This is an important distinction when interpreting sleep-related findings. A patient may report better perceived sleep quality while the medicine also carries a risk of daytime drowsiness or impaired alertness.
The available post-hoc analysis does not establish that improved nighttime sleep translates into better daytime functioning or reduced daytime sleepiness in every patient.
The medicine also has warnings concerning liver enzyme elevations.
In the controlled clinical programme, alanine or aspartate aminotransferase elevations reaching at least three times the upper limit of normal occurred in 0.6% of elinzanetant-treated patients and 0.4% of placebo-treated patients during the initial 12 weeks.
The prescribing information calls for liver-related laboratory assessment before treatment and follow-up testing approximately three months after initiation.
LYNKUET is also contraindicated during pregnancy because of potential pregnancy loss or stillbirth, based on nonclinical evidence.
Additional warnings address seizure risk and clinically relevant drug interactions, including those involving CYP3A4 inhibitors or inducers.
In the longer-term OASIS-3 safety study, headache occurred in 9.6% of elinzanetant-treated patients compared with 7.0% receiving placebo.
Fatigue was reported in 7.3% versus 2.9%, dizziness in 6.1% versus 1.9%, and somnolence in 5.1% versus 1.3%.
These findings demonstrate why a favourable sleep-disturbance result should not be interpreted as evidence that the medicine is free from central nervous system or other clinically important adverse effects.
The full benefit-risk profile remains relevant when evaluating treatment options for menopausal vasomotor symptoms.
How does LYNKUET compete with VEOZAH and other nonhormonal menopause treatments?
The market for nonhormonal treatments of menopausal vasomotor symptoms has expanded as pharmaceutical developers have advanced medicines targeting neurokinin signalling.
Astellas Pharma’s VEOZAH (fezolinetant) received United States approval in May 2023 for moderate to severe vasomotor symptoms due to menopause.
VEOZAH is a neurokinin 3 receptor antagonist, while LYNKUET blocks both NK1 and NK3 receptors.
The difference in receptor activity provides a pharmacological distinction, but it does not independently establish that one medicine is more effective than the other in reducing hot flashes or improving sleep.
No head-to-head clinical evidence was presented in the October Bayer announcement.
Both medicines have demonstrated efficacy against menopausal vasomotor symptoms in their respective clinical programmes, but comparisons of isolated endpoint results across separate trials can be unreliable.
The patient populations, baseline symptoms, treatment schedules and statistical methods may differ.
Safety requirements are also relevant.
VEOZAH carries a United States boxed warning concerning rare but serious liver injury, with associated laboratory monitoring requirements.
LYNKUET has its own warnings concerning liver enzyme elevations, central nervous system depression, pregnancy-related risks and seizures.
The medicines should therefore not be ranked on safety using isolated adverse-event percentages from separate trials.
For Bayer, the new sleep findings may help explain the broader symptom-related experience observed in its Phase 3 programme.
However, commercial differentiation will depend on clinical outcomes, safety requirements, physician familiarity, patient preferences and reimbursement access rather than a descriptive post-hoc analysis alone.
Hormone therapy and other established approaches also remain relevant to the overall treatment landscape, although suitability depends on individual clinical circumstances.
What does the ongoing OASIS-4 regulatory review mean for Bayer’s women’s health strategy?
Bayer is also pursuing an additional United States indication for elinzanetant involving vasomotor symptoms associated with endocrine therapy for hormone receptor-positive breast cancer.
In September 2026, the FDA accepted the company’s supplemental new drug application and granted Priority Review for this proposed use.
The application is supported by the Phase 3 OASIS-4 study, which evaluated elinzanetant in women experiencing vasomotor symptoms while receiving endocrine therapy for the treatment or prevention of breast cancer.
The development is separate from the approved menopause indication and from the October 2026 post-hoc sleep analysis.
Vasomotor symptoms associated with breast cancer endocrine therapy can create substantial treatment-related burden, particularly when conventional hormonal management approaches may be inappropriate.
The OASIS-4 programme is intended to determine whether nonhormonal neurokinin receptor inhibition provides a clinically useful option for that population.
Bayer has reported significant reductions in vasomotor symptom frequency and improvements in selected secondary outcomes, including sleep disturbance, within the trial.
The medicine has already obtained authorisation for this additional use in certain markets, including the United Kingdom, Switzerland and Canada, according to Bayer’s September disclosure.
However, those decisions do not constitute United States approval.
The FDA’s Priority Review designation indicates an expedited review timetable but does not predict the outcome of the supplemental application.
For Bayer, successful expansion into endocrine therapy-associated vasomotor symptoms could provide an additional commercial opportunity beyond the current menopause indication.
The October sleep analysis may contribute to broader scientific discussions around symptom burden, but it does not replace the OASIS-4 evidence required for the new regulatory decision.
What are the commercial implications of Bayer’s additional LYNKUET sleep findings?
Bayer’s latest disclosure concerns an approved product rather than an investigational medicine awaiting its first marketing authorisation.
Consequently, the immediate commercial significance differs from that of a pivotal trial success or a new regulatory approval.
The findings may provide additional information for healthcare professionals evaluating the patient experience associated with treatment of menopausal vasomotor symptoms.
However, the individual sleep questionnaire results do not change the approved indication or establish a new reimbursement category for sleep disorders.
Any effect on prescribing will depend on how clinicians interpret the evidence in the context of the existing label, alternative therapies and the medicine’s safety requirements.
Bayer’s broader pharmaceutical business remains substantially influenced by established medicines such as NUBEQA and KERENDIA, alongside the effects of patent expirations affecting older products.
In the second quarter of 2026, Bayer reported group sales of approximately €10.87 billion. Pharmaceuticals revenue remained broadly in line with the previous year on a currency- and portfolio-adjusted basis, as growth in newer products offset declines in several established medicines.
LYNKUET forms part of the company’s effort to expand its women’s healthcare portfolio, but Bayer has not disclosed a specific incremental revenue forecast attributable to the October 2026 sleep analysis.
The commercial opportunity will be influenced by market access, physician adoption, patient persistence and the potential expansion of the approved treatment population.
Bayer shares closed at €45.56 on October 26, 2026, rising approximately 3.6% from the previous session’s €43.98 closing price.
The advance should not be attributed to the sleep analysis. The Business Wire announcement was issued after the German regular trading session, and the share-price movement occurred against the background of broader company and market developments.
The post-hoc disclosure is best characterised as an incremental product-evidence update rather than a new financial catalyst.
What further evidence could establish whether LYNKUET improves clinically meaningful sleep outcomes?
The original OASIS studies demonstrated statistically significant improvement in the overall PROMIS sleep-disturbance T-score.
The new analysis provides additional descriptive information about which self-reported sleep experiences improved during treatment.
A useful next research question is whether these changes are primarily mediated through reductions in nighttime vasomotor symptoms or reflect additional pharmacological effects.
Analyses linking the timing and severity of nighttime hot flashes with individual sleep-disturbance outcomes could help clarify that relationship.
Research incorporating objective sleep measurements might also strengthen the clinical interpretation.
For example, carefully designed studies using actigraphy or polysomnography could examine sleep continuity, wake time after sleep onset and other physiological measures alongside patient-reported outcomes.
Such research would be particularly relevant if future development seeks to investigate sleep-specific claims rather than describe sleep disturbance within a vasomotor symptom treatment programme.
Longer-term evidence could also help establish whether perceived sleep improvements persist beyond the first 12 weeks and whether they are associated with measurable changes in daytime functioning or quality of life.
The generalisability of the current findings remains another consideration.
OASIS-1 and OASIS-2 enrolled women meeting specific eligibility criteria, so the results may not represent every patient encountered in routine menopause care.
Future real-world studies could provide information about treatment persistence, patient experiences and outcomes among more diverse clinical populations.
However, observational evidence would need careful interpretation because differences in underlying health, concomitant treatments and symptom severity can influence reported sleep quality.
What do the new LYNKUET sleep findings establish for menopause treatment?
Bayer’s October 2026 post-hoc analysis provides additional detail about the sleep-related experiences of women receiving elinzanetant for moderate to severe menopausal vasomotor symptoms.
The reported decline in poor or very poor sleep quality from 66.6% to 20.5% after 12 weeks is encouraging, particularly when compared with the smaller descriptive improvement observed in the placebo group.
The findings are consistent with previously published Phase 3 evidence demonstrating statistically significant improvement in the overall PROMIS sleep-disturbance score.
However, the individual questionnaire results were exploratory and were not supported by formal statistical testing. They also do not establish objective sleep improvement or efficacy in treating insomnia independently of menopausal vasomotor symptoms.
For clinicians, the appropriate interpretation is that LYNKUET’s approved vasomotor symptom treatment may be accompanied by improvements in patient-perceived sleep disturbance, while its established safety requirements remain important.
For Bayer, the findings add depth to the clinical profile of a recently approved nonhormonal menopause treatment and support continued research into broader symptom-related outcomes.
The most consequential next developments will involve the ongoing regulatory review of the proposed endocrine therapy-associated vasomotor symptom indication and further evidence clarifying the durability and clinical significance of sleep-related improvements.
LYNKUET’s established benefit remains the reduction of moderate to severe menopausal hot flashes. The new analysis helps explain how that treatment may relate to women’s wider symptom experience, without independently creating a new therapeutic indication.
